Award-winning Agilex Biolabs, the Asia-Pacific region’s leading bioanalytical laboratory based in Australia, announced a raft of new pharmacodynamics services for biotech and pharma clients conducting preclinical and clinical trials in Asia, US, EU and Australia.

Agilex Biolabs CEO Jason Valentine made the announcement at J.P. Morgan Healthcare Conference and the Biotech Showcase this week. The additional pharmacodynamics services are in new labs at the Agilex Biolabs facility in Australia.

The services include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:

• Immunophenotyping
• Receptor occupancy
• Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling

• PBMC assays and cellular mechanism of action assays (eg: ADCC)

Agilex Biolabs, the only FDA-inspected lab of its type in the Asia-Pacific, offers bioanalysis for small molecules and biologics for PK, immunogenicity and biomarkers utilising the two platforms of LC-MS/MS (7) and Immunoassay (MesoScale, Gyrolab).

CEO Jason Valentine said, “Our FDA-inspected facilities have more than 60 dedicated laboratory staff, and annually support more than 80 clinical trials. This year we will analyse more than 60,000 samples for pharma/biotechs from the US, Europe and APAC. By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world.”

He further said compliance is key to the Agilex Biolabs success, "Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition."